-
1
-
-
0028070503
-
Inhibition of ribonucleotide reductase by 2′-substituted deoxycytidine analogs: Possible application in AIDS treatment
-
Blanchi V, Borella S, Calderazzo F, Ferraro P, Chieco Bianchi L, Reichard P. Inhibition of ribonucleotide reductase by 2′-substituted deoxycytidine analogs: possible application in AIDS treatment. Proc Natl Acad Sci USA 1994;91:8403-7.
-
(1994)
Proc Natl Acad Sci USA
, vol.91
, pp. 8403-8407
-
-
Blanchi, V.1
Borella, S.2
Calderazzo, F.3
Ferraro, P.4
Chieco Bianchi, L.5
Reichard, P.6
-
2
-
-
0027976787
-
Restriction and enhancement of human immunodeficiency virus type 1 replication by modulation of intracellular deoxynucleoside triphosphate pools
-
Meyerhans A, Vartanian JP, Hultgren C, et al. Restriction and enhancement of human immunodeficiency virus type 1 replication by modulation of intracellular deoxynucleoside triphosphate pools. J Virol 1994;68:535-40.
-
(1994)
J Virol
, vol.68
, pp. 535-540
-
-
Meyerhans, A.1
Vartanian, J.P.2
Hultgren, C.3
-
3
-
-
0027377963
-
Low levels of deoxynucleotides in peripheral blood lymphocytes: A strategy to inhibit human immunodeficiency virus type 1 replication
-
Gao WY, Cara A, Gallo RC, Lori F. Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proc Natl Acad Sci USA 1993;90:8925-8.
-
(1993)
Proc Natl Acad Sci USA
, vol.90
, pp. 8925-8928
-
-
Gao, W.Y.1
Cara, A.2
Gallo, R.C.3
Lori, F.4
-
4
-
-
0027948936
-
Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication
-
Lori F, Malykh A, Cara A, et al. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 1994; 266:801-5.
-
(1994)
Science
, vol.266
, pp. 801-805
-
-
Lori, F.1
Malykh, A.2
Cara, A.3
-
5
-
-
0028019710
-
Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2′,3′-dideoxynucleosides
-
Gao WY, Johns DG, Mitsuya H. Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2′,3′-dideoxynucleosides. Mol Pharmacol 1994;46:767-72.
-
(1994)
Mol Pharmacol
, vol.46
, pp. 767-772
-
-
Gao, W.Y.1
Johns, D.G.2
Mitsuya, H.3
-
6
-
-
0028116945
-
Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2′,3′-dideoxyinosine in infected resting human lymphocytes
-
Malley SD, Grange JM, Hamedi-Sangsari F, Vila JR. Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2′,3′-dideoxyinosine in infected resting human lymphocytes. Proc Natl Acad Sci USA 1994;91:11017-21.
-
(1994)
Proc Natl Acad Sci USA
, vol.91
, pp. 11017-11021
-
-
Malley, S.D.1
Grange, J.M.2
Hamedi-Sangsari, F.3
Vila, J.R.4
-
7
-
-
0029086336
-
Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2′,3′-dideoxynucleoside activities against replication of human immunodeficiency virus
-
Gao WY, Johns DG, Chokekuchai S, Mitsuya H. Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2′,3′-dideoxynucleoside activities against replication of human immunodeficiency virus. Proc Natl Acad Sci USA 1995;92:8333-7.
-
(1995)
Proc Natl Acad Sci USA
, vol.92
, pp. 8333-8337
-
-
Gao, W.Y.1
Johns, D.G.2
Chokekuchai, S.3
Mitsuya, H.4
-
8
-
-
0030831543
-
Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance
-
Lori F, Malykh AG, Foli A, et al. Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance. AIDS Res Hum Retroviruses 1997;13:1403-9.
-
(1997)
AIDS Res Hum Retroviruses
, vol.13
, pp. 1403-1409
-
-
Lori, F.1
Malykh, A.G.2
Foli, A.3
-
9
-
-
0031693813
-
Pharmacokinetics, safety and anti-human immunodeficiency virus (HIV) activity of hydroxyurea in combination with didanosine
-
Luzzati R, Di Perri G, Fendt D, Ramarli D, Broccali G, Concia E. Pharmacokinetics, safety and anti-human immunodeficiency virus (HIV) activity of hydroxyurea in combination with didanosine. J Antimicrob Chemother 1998;42:565-6.
-
(1998)
J Antimicrob Chemother
, vol.42
, pp. 565-566
-
-
Luzzati, R.1
Di Perri, G.2
Fendt, D.3
Ramarli, D.4
Broccali, G.5
Concia, E.6
-
10
-
-
0029086733
-
Anti-HIV activity of the combination of didanosine and hydroxyurea in HIV-1-infected individuals
-
Biron F, Lucht F, Peyramond D, et al. Anti-HIV activity of the combination of didanosine and hydroxyurea in HIV-1-infected individuals. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10: 36-40.
-
(1995)
J Acquir Immune Defic Syndr Hum Retrovirol
, vol.10
, pp. 36-40
-
-
Biron, F.1
Lucht, F.2
Peyramond, D.3
-
11
-
-
18544411156
-
Pilot clinical trial of the combination of hydroxyurea and didanosine in HIV-1 infected individuals
-
Biron F, Lucht F, Peyramond D, et al. Pilot clinical trial of the combination of hydroxyurea and didanosine in HIV-1 infected individuals. Antiviral Res 1996;29:111-3.
-
(1996)
Antiviral Res
, vol.29
, pp. 111-113
-
-
Biron, F.1
Lucht, F.2
Peyramond, D.3
-
12
-
-
0030956535
-
A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV trials network protocol 080
-
Montaner JS, Zala C, Conway B, et al. A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV trials network protocol 080. J Infect Dis 1997;175:801-6.
-
(1997)
J Infect Dis
, vol.175
, pp. 801-806
-
-
Montaner, J.S.1
Zala, C.2
Conway, B.3
-
13
-
-
0029933819
-
Peyramond D. 1-year follow-up of the use of hydroxycarbamide and didanosine in HIV infection
-
Vila J, Biron F, Nugier F, Vallet T, Peyramond D. 1-year follow-up of the use of hydroxycarbamide and didanosine in HIV infection. Lancet 1996;348:203-4.
-
(1996)
Lancet
, vol.348
, pp. 203-204
-
-
Vila, J.1
Biron, F.2
Nugier, F.3
Vallet, T.4
-
14
-
-
0030055872
-
Treatment of human immunodeficiency virus infection with hydroxyurea: Virologie and clinical evaluation
-
Giacca M, Zanussi S, Comar M, et al. Treatment of human immunodeficiency virus infection with hydroxyurea: virologie and clinical evaluation. J Infect Dis 1996;174:204-9.
-
(1996)
J Infect Dis
, vol.174
, pp. 204-209
-
-
Giacca, M.1
Zanussi, S.2
Comar, M.3
-
15
-
-
7144257857
-
A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study
-
Rutschmann OT, Opravil M, Iten A, et al. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study. AIDS 1998;12: F71-7.
-
(1998)
AIDS
, vol.12
-
-
Rutschmann, O.T.1
Opravil, M.2
Iten, A.3
-
16
-
-
0032524983
-
Selective depletion of DNA precursors: An evolving strategy for potentiation of dideoxynucleoside activity against human immunodeficiency virus
-
Johns DG, Gao WY. Selective depletion of DNA precursors: an evolving strategy for potentiation of dideoxynucleoside activity against human immunodeficiency virus. Biochem Pharmacol 1998;55:1551-6.
-
(1998)
Biochem Pharmacol
, vol.55
, pp. 1551-1556
-
-
Johns, D.G.1
Gao, W.Y.2
-
17
-
-
0032504930
-
Target cell availability and the successful suppression of HIV by hydroxyurea and didanosine
-
De Boer RJ, Boucher CA, Perelson AS. Target cell availability and the successful suppression of HIV by hydroxyurea and didanosine. AIDS 1998;12:1567-70.
-
(1998)
AIDS
, vol.12
, pp. 1567-1570
-
-
De Boer, R.J.1
Boucher, C.A.2
Perelson, A.S.3
-
18
-
-
0003290066
-
Ziagen/combivir is equivalent to indinavir/combivir in antiretroviral therapy naive adults at 24 weeks
-
Chicago
-
Staszeweski S, Keiser P, Gathe J, et al. Ziagen/combivir is equivalent to indinavir/combivir in antiretroviral therapy naive adults at 24 weeks [abstract 20]. Presented at the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999.
-
(1999)
6th Conference on Retroviruses and Opportunistic Infections
-
-
Staszeweski, S.1
Keiser, P.2
Gathe, J.3
-
19
-
-
0025847662
-
In vitro immunosuppressive effects of mycophenolic acid and an ester pro-drug, RS-61443
-
Allison AC, Almquist SJ, Muller CD, Eugui EM. In vitro immunosuppressive effects of mycophenolic acid and an ester pro-drug, RS-61443. Transplant Proc 1991;23(Suppl 2): 10-4.
-
(1991)
Transplant Proc
, vol.23
, Issue.SUPPL. 2
, pp. 10-14
-
-
Allison, A.C.1
Almquist, S.J.2
Muller, C.D.3
Eugui, E.M.4
-
21
-
-
0027717956
-
Characterization of human type I and type II IMP dehydrogenases
-
Carr SF, Papp E, Wu JC, Natsumeda Y. Characterization of human type I and type II IMP dehydrogenases. J Biol Chem 1993;268: 27286-90.
-
(1993)
J Biol Chem
, vol.268
, pp. 27286-27290
-
-
Carr, S.F.1
Papp, E.2
Wu, J.C.3
Natsumeda, Y.4
-
22
-
-
0029116425
-
Polymerase substrate depletion: A novel strategy for inhibiting the replication of the human immunodeficiency virus
-
Ichimura H, Levy JA. Polymerase substrate depletion: a novel strategy for inhibiting the replication of the human immunodeficiency virus. Virology 1995;211:554-60.
-
(1995)
Virology
, vol.211
, pp. 554-560
-
-
Ichimura, H.1
Levy, J.A.2
-
23
-
-
0031952851
-
The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo
-
Neyts J, Andrei G, De Clercq E. The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo. Antimicrob Agents Chemother 1998;42:216-22.
-
(1998)
Antimicrob Agents Chemother
, vol.42
, pp. 216-222
-
-
Neyts, J.1
Andrei, G.2
De Clercq, E.3
-
24
-
-
0031758701
-
The antiherpesvirus activity of H2G is markedly enhanced by the novel immunosuppressive agent mycophenolate mofetil
-
Neyts J, Andrei G, De Clercq E. The antiherpesvirus activity of H2G is markedly enhanced by the novel immunosuppressive agent mycophenolate mofetil. Antimicrob Agents Chemother 1998;42: 3285-9.
-
(1998)
Antimicrob Agents Chemother
, vol.42
, pp. 3285-3289
-
-
Neyts, J.1
Andrei, G.2
De Clercq, E.3
-
25
-
-
0021237243
-
Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre AIDS
-
Popovic M, Sarngadharan MG, Read E, Gallo RC. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre AIDS. Science 1984; 224:497.
-
(1984)
Science
, vol.224
, pp. 497
-
-
Popovic, M.1
Sarngadharan, M.G.2
Read, E.3
Gallo, R.C.4
-
26
-
-
0023681241
-
Distinct biological and serological properties of human immunodeficiency viruses from the brain
-
Chenge-Mayer C, Levy JA. Distinct biological and serological properties of human immunodeficiency viruses from the brain. Ann Neurol 1988;23:S58.
-
(1988)
Ann Neurol
, vol.23
-
-
Chenge-Mayer, C.1
Levy, J.A.2
-
27
-
-
0027409698
-
Characterization of human immunodeficiency viruses resistant to oxathiolance-cytosine nucleosides
-
Schinazy RF, Lloyd RM Jr, Nguyen MH, et al. Characterization of human immunodeficiency viruses resistant to oxathiolance-cytosine nucleosides. Antimicrob Agents Chemother 1993;37:875.
-
(1993)
Antimicrob Agents Chemother
, vol.37
, pp. 875
-
-
Schinazy, R.F.1
Lloyd R.M., Jr.2
Nguyen, M.H.3
-
28
-
-
0344034052
-
-
NIH Pub No. 94 3828. Bethesda, MD: National Institutes of Health
-
ACTG virology manual, NIH Pub No. 94 3828. Bethesda, MD: National Institutes of Health, 1994.
-
(1994)
ACTG Virology Manual
-
-
-
29
-
-
0022404296
-
Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in plaque assay
-
Harada S, Koyanagi Y, Yamamoto N. Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in plaque assay. Science 1985;229:563.
-
(1985)
Science
, vol.229
, pp. 563
-
-
Harada, S.1
Koyanagi, Y.2
Yamamoto, N.3
-
31
-
-
0029036955
-
The search for synergy: A critical review from a response surface perspective
-
Greco WR, Bravo G, Parsons JC. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 1995; 47:331-85.
-
(1995)
Pharmacol Rev
, vol.47
, pp. 331-385
-
-
Greco, W.R.1
Bravo, G.2
Parsons, J.C.3
-
33
-
-
0003910309
-
-
Research Triangle Park, NC: Glaxo Wellcome, Inc.
-
Ziagen package insert. Research Triangle Park, NC: Glaxo Wellcome, Inc., 1999.
-
(1999)
Ziagen Package Insert
-
-
-
34
-
-
0344465148
-
-
Nutley, NJ: Roche Laboratories
-
Cellcept package insert. Nutley, NJ: Roche Laboratories, 1998.
-
(1998)
Cellcept Package Insert
-
-
-
35
-
-
0029917782
-
Pharmacokinetics of mycophenolate mofetil (RS61443): A short review
-
Bullingham RES, Nicholls A, Hale M. Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Transplant Proc 1996;28:925-9.
-
(1996)
Transplant Proc
, vol.28
, pp. 925-929
-
-
Bullingham, R.E.S.1
Nicholls, A.2
Hale, M.3
-
36
-
-
0031596029
-
Nucleoside analog 1592U89 and human immunodeficiency virus protease inhibitor 141W94 are synergistic in vitro
-
Drusano GL, D'Argenio DZ, Symonds W, et al. Nucleoside analog 1592U89 and human immunodeficiency virus protease inhibitor 141W94 are synergistic in vitro. Antimicrob Agents Chemother 1998;42:2153-9.
-
(1998)
Antimicrob Agents Chemother
, vol.42
, pp. 2153-2159
-
-
Drusano, G.L.1
D'Argenio, D.Z.2
Symonds, W.3
-
37
-
-
0030945276
-
Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89
-
Tisdale M, Alnadaf T, Cousens D. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob Agents Chemother 1997;41:1094-8.
-
(1997)
Antimicrob Agents Chemother
, vol.41
, pp. 1094-1098
-
-
Tisdale, M.1
Alnadaf, T.2
Cousens, D.3
-
38
-
-
0000498539
-
Analysis of possible predictors of response to abacavir (ABC) in antiretroviral-experienced adults; comparison of viral genotype, viral phenotype and patient treatment history
-
Chicago
-
Lanier R, Ait-Khaled M, Madison S, et al. Analysis of possible predictors of response to abacavir (ABC) in antiretroviral-experienced adults; comparison of viral genotype, viral phenotype and patient treatment history [abstract 134]. Presented at the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999.
-
(1999)
6th Conference on Retroviruses and Opportunistic Infections
-
-
Lanier, R.1
Ait-Khaled, M.2
Madison, S.3
-
39
-
-
0023122258
-
Ribavirin antagonizes the effect of azidothymidine on HIV replication
-
Vogt M W, Hartshorrn KL, Furman PA, et al. Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 1987;235:1376-9.
-
(1987)
Science
, vol.235
, pp. 1376-1379
-
-
Vogt, M.W.1
Hartshorrn, K.L.2
Furman, P.A.3
-
40
-
-
0023636684
-
Ribavirin antagonizes inhibitory effects of purine 2′,3′-dideoxynucleosides on replication of human immunodeficiency vi-rus in vitro
-
Baba M, Pauwels R, Balzarini J, Herdewijn P, DeClercq E, Desmyter J. Ribavirin antagonizes inhibitory effects of purine 2′,3′-dideoxynucleosides on replication of human immunodeficiency vi-rus in vitro. Antimicrob Agents Chemother 1987;31:1613-17.
-
(1987)
Antimicrob Agents Chemother
, vol.31
, pp. 1613-1617
-
-
Baba, M.1
Pauwels, R.2
Balzarini, J.3
Herdewijn, P.4
DeClercq, E.5
Desmyter, J.6
-
41
-
-
0025773889
-
Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the anti-human immunodeficiency virus nucleosides 2′,3′-dideoxyadenosine and 2′,3′-dideoxyinosine
-
Hartman NR, Ahluwalia GS, Cooney DA, et al. Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the anti-human immunodeficiency virus nucleosides 2′,3′-dideoxyadenosine and 2′,3′-dideoxyinosine. Mol Pharmacol 1991;40:118-24.
-
(1991)
Mol Pharmacol
, vol.40
, pp. 118-124
-
-
Hartman, N.R.1
Ahluwalia, G.S.2
Cooney, D.A.3
-
43
-
-
0027094084
-
Comparison of the effects of mizoribine with those of azathioprine, 6-mercaptopurine, and mycophenolic acid on T-lymphocyte proliferation and purine ribonucleotide metabolism
-
Dayton JS, Turka LA, Thompson CB, Mitchell BS. Comparison of the effects of mizoribine with those of azathioprine, 6-mercaptopurine, and mycophenolic acid on T-lymphocyte proliferation and purine ribonucleotide metabolism. Mol Pharmacol 1994;41:671-676.
-
(1994)
Mol Pharmacol
, vol.41
, pp. 671-676
-
-
Dayton, J.S.1
Turka, L.A.2
Thompson, C.B.3
Mitchell, B.S.4
|